膀胱过度活动症药物持久性与依从性的系统评价与网络Meta分析
该系统评价与网络Meta分析检索PubMed、Cochrane Library和EMBASE至2019年5月21日,评估抗胆碱能药与米拉贝隆治疗膀胱过度活动症的持久性和依从率。12个月总体持久率为0.218(95%CI:0.197-0.240),总体依从率为0.589(95%CI:0.507-0.670),持久性与依从率低于既往报告并与年龄、性别等因素相关。
要点
- 12个月总体持久率仅0.218,米拉贝隆0.402高于索利那新0.249和非索罗定0.220。
- 总体依从率0.589,12个月依从率米拉贝隆0.654、索利那新0.784、非索罗定0.782、咪达那新0.679。
- 持久性与依从率与年龄、性别、抗胆碱能暴露史、药物类型、研究类型和研究年份相关。
核心结论
- 膀胱过度活动症药物的持久性和依从率低于既往报告,并与某些临床和人口学因素相关。
研究设计与样本
- 系统评价与Meta分析及网络Meta分析,检索PubMed、Cochrane Library和EMBASE自最早索引至2019年5月21日的英文文献。
主要发现
- 抗胆碱能药与米拉贝隆12个月总体持久率为0.218(95%CI:0.197-0.240)。
- 12个月持久率:米拉贝隆0.402(95%CI:0.277-0.528)、索利那新0.249(95%CI:0.182-0.316)、非索罗定0.220(95%CI:0.078-0.361)。
- 抗胆碱能药与米拉贝隆总体依从率为0.589(95%CI:0.507-0.670)。
- 12个月依从率:米拉贝隆0.654(95%CI:0.528-0.781)、索利那新0.784(95%CI:0.588-0.980)、非索罗定0.782(95%CI:0.652-0.911)、咪达那新0.679(95%CI:0.651-0.707)。
- 持久性和依从率与年龄、性别、抗胆碱能暴露史、药物类型、研究类型和研究年份相关。
临床怎么用
- 临床应关注膀胱过度活动症药物治疗的长期持久性与依从性,尤其老年、男性及有抗胆碱能暴露史者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to investigate the persistence and adherence rate of overactive bladder medications and factors that affect these rates. MATERIALS AND METHODS: We conducted electronic English-language literature searches of the PubMed®, Cochrane Library, and EMBASE® databases from the earliest available date of indexing through May 21, 2019 using the Medical Subject Headings (MeSH) terms and EMBASE subject headings (Emtree). Primary measurement outcomes were overall persistence and adherence rate at 6, 12, 24, and 36 months in anticholinergics and mirabegron. Secondary outcomes were individual effect of each medication on persistence and adherence rate at 12 months, and moderating factors affecting the overall persistence and adherence rate at 12 months. RESULTS: Pooled overall persistence rate at 12 months of overactive bladder medications of anticholinergics and mirabegron was 0.218 (95% CI: 0.197-0.240). The pooled overall persistence rate at 12 months was 0.402 (95% CI: 0.277-0.528) in mirabegron, 0.249 (95% CI: 0.182-0.316) in solifenacin, and 0.220 (95% CI: 0.078-0.361) in fesoterodine. Overall adherence rate of overactive bladder medications of anticholinergics and mirabegron was 0.589 (95% CI: 0.507-0.670). The pooled overall adherence rate at 12 months was 0.654 (95% CI: 0.528-0.781) in mirabegron, 0.784 (95% CI: 0.588-0.980) in solifenacin, 0.782 (95% CI: 0.652-0.911) in fesoterodine, and 0.679 (95% CI: 0.651-0.707) in imidafenacin. Persistence and adherence rates were associated with age, gender, anticholinergic exposure history, type of medication, study type, and study year. CONCLUSIONS: Persistence and adherence rates were lower than previously reported and were associated with certain clinical and demographic factors.
引用
- Song YS, Lee HY, Park JJ, et al. Persistence and Adherence of Anticholinergics and Beta-3 Agonist for the Treatment of Overactive Bladder: Systematic Review and Meta-Analysis, and Network Meta-Analysis. J Urol. 2020. PMID: 33207141. doi:10.1097/JU.0000000000001440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。